Lead Product(s) : GLPG3970
Therapeutic Area : Dermatology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Galapagos Announces First Dosing with Toledo Compound GLPG3970 in Psoriasis Trial
Details : Patient enrolled in the Calosoma Phase 1 trial, a double-blind, placebo-controlled study evaluating the safety, tolerability, PK and PD1 of GLPG3970 single and multiple ascending doses in up to 52 adult healthy male subjects.
Product Name : GLPG3970
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
September 29, 2020
Lead Product(s) : GLPG3970
Therapeutic Area : Dermatology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : GLPG3667
Therapeutic Area : Dermatology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
First Patient Dosed with Galapagos' GLPG3667 in Psoriasis Patient Phase 1b Trial
Details : This Phase 1b trial is a randomized, double-blind, placebo-controlled, multicenter study to evaluate the safety, tolerability, efficacy, pharmacokinetics, and pharmacodynamics of GLPG3667.
Product Name : GLPG3667
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
September 11, 2020
Lead Product(s) : GLPG3667
Therapeutic Area : Dermatology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable